Meropenem-Tchaikapharma

Meropenem, the active ingredient in Meropenem‑Tchaikapharma, is a carbapenem antibiotic presented as an intravenous solution for parenteral use. It treats severe bacterial infections such as intra‑abdominal infections, urinary tract infections, pneumonia and septicemia in hospitalized patients.

GNH USA supplies Meropenem‑Tchaikapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a carbapenem antibiotic used to manage serious bacterial infections by targeting a broad spectrum of Gram‑negative and Gram‑positive organisms.

- Complicated intra‑abdominal infections: achieves clinical cure and bacterial eradication. - Complicated urinary tract infections: provides rapid resolution of infection and prevents recurrence. - Hospital‑acquired pneumonia: effective in attaining microbiological clearance and improving respiratory function. - Septicemia: rapidly reduces bacteremia and supports hemodynamic stabilization.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient and usually resolves without intervention. - Rash: mild erythematous skin eruptions. - Elevated liver enzymes: transient increase in hepatic transaminases. - Injection site pain: discomfort at the IV site.

Serious or Rare Side Effects: - Seizures: especially in patients with CNS disorders or renal impairment. - Clostridioides difficile‑associated diarrhea: severe colitis requiring prompt treatment. - Anaphylaxis: acute, potentially life‑threatening allergic reaction. - Renal toxicity: acute kidney injury in susceptible individuals. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Use meropenem with careful clinical monitoring and consider patient‑specific factors.

- Renal function: adjust dose in patients with impaired kidney function. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Seizure risk: monitor closely in patients with a history of seizures or CNS disease. - Valproic acid co‑administration: avoid due to increased seizure risk. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid): - Valproic acid: may precipitate seizures. - CNS depressants: additive central nervous system depression. - High‑dose aminoglycosides: increased risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - Other carbapenems: assess for cumulative toxicity. - Warfarin or other anticoagulants: monitor INR for possible elevation. - Loop diuretics: watch renal function and electrolytes. - Vancomycin: monitor for combined nephrotoxic effects.